Trial reportNutrition & diabetes2025
Effects of vitamin D supplementation on metabolic factors, serum omentin-1, and anthropometric indices in middle-aged women with prediabetes: a double-blind randomized controlled trial.
Trial report in Nutrition & diabetes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundPrediabetes is a public health concern, and its prevalence is growing around the world. Providing an effective strategy to prevent prediabetes progression and, consequently, type-2 diabetes mellitus (T2DM) could be useful for global health. The present study aimed to investigate the impact of vitamin D supplementation on metabolic factors, serum omentin-1 levels, and anthropometric indices in women with prediabetes.
methodsThis randomized controlled trial (RCT) study was carried out on women with prediabetes aged 18-65 years. The women were allocated to the intervention (n = 48) or placebo (n = 48) groups to receive vitamin D (50000 IU) or a placebo every two weeks for 12 weeks, respectively. Fasting blood samples, anthropometric measurements, and information about the dietary intake and physical activity of the participants were collected at the beginning and after the intervention. Data analyses were done using IBM SPSS Statistics software.
resultsVitamin D intervention significantly enhanced 25-hydroxyvitamin D (MD (CI 95%): 11.610 ng/ml (8.264, 14.956)), insulin (MD (CI 95%): 0.413 µIU/mL (0.321, 0.505)), Homeostatic Model Assessment of Insulin Resistance (MD (CI 95%): 0.411 (0.319, 0.502)), and Homeostatic Model Assessment of Insulin Resistance-β cell function (MD (CI 95%): 29.505% (22.114, 36.986)) levels compared to the placebo at the end of trial (all, p < 0.05). Moreover, a significant reduction in QUICKI was observed after the intervention (MD (CI 95%): -0.062 (-0.076, -0.048)). Changes in fasting blood sugar (FBS), lipid profiles, omentin-1 levels, and anthropometric indices were not significant between the groups after the intervention.
conclusionThe findings revealed that vitamin D administration improved insulin secretion but failed to affect FBS, lipid profiles, anthropometric indices, and body composition in women with prediabetes. Due to inconsistent results, more well-designed RCTs are required to clarify the effects of vitamin D supplementation on these patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.